Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Geron ( (GERN) ) has provided an announcement.
On January 5, 2026, Geron Corporation amended its existing senior secured term loan facility with investment funds managed by Pharmakon Advisors, maintaining a total capacity of up to $250 million across three tranches tied in part to revenue milestones for its product RYTELO™. The amendment primarily extends the deadline to draw the $75 million Tranche B and $50 million Tranche C loans from December 31, 2025 to July 30, 2026, and pushes the makewhole protection date for lenders from November 1, 2026 to May 1, 2027, giving Geron additional flexibility in timing future borrowings while preserving lender economics and potentially supporting its funding needs and growth plans.
The most recent analyst rating on (GERN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.
Spark’s Take on GERN Stock
According to Spark, TipRanks’ AI Analyst, GERN is a Neutral.
Geron’s overall score reflects financial challenges with profitability and cash flow, despite positive revenue growth and a strong gross profit margin. Technical indicators show moderate bullish momentum, but valuation is impacted by a negative P/E ratio. The earnings call and corporate events highlight both strategic initiatives and operational challenges.
To see Spark’s full report on GERN stock, click here.
More about Geron
Geron Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapeutics, including its product RYTELO™, targeting specialized areas of the healthcare market.
Average Trading Volume: 7,587,957
Technical Sentiment Signal: Sell
Current Market Cap: $842.6M
For an in-depth examination of GERN stock, go to TipRanks’ Overview page.